Status:
COMPLETED
Role of Anti-Inflammatory Agents in Patients With Schizophrenia
Lead Sponsor:
Pakistan Institute of Living and Learning
Collaborating Sponsors:
Karwan e Hayat
Dow University of Health Sciences
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
There is some evidence that anti-inflammatory treatment may have beneficial effects in schizophrenia and major depression. Cox-2 inhibitors have been tested in preliminary clinical trials for schizoph...
Eligibility Criteria
Inclusion
- Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder
- competent and willing to give informed consent
- stable on medication 4 weeks prior to baseline
- able to take oral medication and likely to complete the required evaluations
- female participants of child bearing age must be willing to use adequate contraceptives for the duration of the study, and, willing to have a pregnancy test pre treatment and at ten weekly intervals while on study medication.
Exclusion
- Relevant medical illness \[renal and hepatic\] in the opinion of the investigators
- history of high alcohol intake
- any change of psychotropic medications within the previous six weeks
- diagnosis of substance abuse (except nicotine or caffeine) or dependence within the last three months according to DSM-IV criteria
- pregnant or breast-feeding.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00929955
Start Date
June 1 2009
End Date
September 1 2010
Last Update
August 5 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dow University of Health Sciences
Karachi, Pakistan
2
Karwan e hayat
Karachi, Pakistan